COMPASS Pathways Announces $150 Million Public Offering

COMPASS Pathways ( (CMPS) ) just unveiled an announcement.

On February 18, 2026, Compass Pathways priced an underwritten public offering of 17.5 million American Depositary Shares at $8.00 each and pre-funded warrants for 1.25 million ADSs at $7.9999, with underwriters granted a 30-day option to buy up to an additional 2.81 million ADSs. The deal, expected to close on or about February 20, 2026, is set to raise $150 million in gross proceeds to support late-stage COMP360 depression and PTSD trials, accelerate commercial readiness, and fund general corporate purposes, while insiders agreed to a 60-day lock-up on share disposals.

The most recent analyst rating on (CMPS) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on COMPASS Pathways stock, see the CMPS Stock Forecast page.

Spark’s Take on CMPS Stock

According to Spark, TipRanks’ AI Analyst, CMPS is a Neutral.

The score is held back primarily by weak financial performance (no revenue, escalating losses/cash burn, and reduced equity with higher leverage). Offsetting this, technicals are trending positively and the latest earnings call highlighted significant Phase III/regulatory progress and a stated cash runway into 2027, while valuation remains constrained by ongoing losses and no dividend.

To see Spark’s full report on CMPS stock, click here.

More about COMPASS Pathways

Compass Pathways plc is a biotechnology company focused on mental health, developing evidence-based innovations for patients with serious conditions who do not respond to existing treatments. Its lead candidate is COMP360, a synthetic psilocybin therapy with U.S. FDA Breakthrough Therapy and UK ILAP designations for treatment-resistant depression, positioning the company at the forefront of psychedelic-based psychiatric care.

Average Trading Volume: 2,061,139

Technical Sentiment Signal: Hold

Current Market Cap: $732.5M

See more insights into CMPS stock on TipRanks’ Stock Analysis page.